WT1 and Miyoshi myopathy: In a case study by Tsuboi et al., a 57-year-old chemotherapy-resistant MM patient received weekly intradermal vaccinations with HLA-A*2402-restricted 9-mer WT1 peptide and montanide ISA51 as an adjuvant.